Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature

Table 1 The clinical characteristics, treatments, and responses of patients in our case

	Case 1	Case 2	Case 3
Age on diagnosis (years)	52	55	53
Pathological diagnosis	SC	SC	SC
Stage	IB3	IIA2	IB3
Primary tumor diameter (maximum, cm)	6.35	5.3	5.9
Before NACT
PD-L1 status	positive	positive	positive
SCC-Ag (ng/ml)	26.9	6.7	8.8
Cytokeratin-19-fragment (ng/ml)	3.93	3.41	6.38
Neutrophil/Lymphocyte	3.54	1.94	2.47
Platelet/Lymphocyte	304.2	131.47	165.33
SIRI = Neutrophil × Monocytes	0.61	0.58	1.78
Pre-surgery
SCC-Ag (ng/ml)	0.6	0.8	1.5
Cytokeratin-19-fragment (ng/ml)	0.76	0.99	1.43
Neutrophil/Lymphocyte	6.36	11.84	1.63
Platelet/Lymphocyte	160.24	90.91	109.27
SIRI = Neutrophil × Monocytes	2.06	5.86	1.16
NACT + ICI (dosage)	Nab-P (260 mg/m²), T (AUC6), Sin (200 mg)	P (135 mg/m²), T (AUC6), Sin (200 mg)	P (135 mg/m²), T (AUC6), Sin (200 mg)
Courses	2	2	2
Response to NACT	pCR	pPR	pPR
Type of surgery	RH + BS + PLND + PALND	RH + BS + PLND + PALND	RH + BS + PLND + PALND
Postoperative treatment	CT + ICI	CRT	CRT
Follow up (mo)	22	16	16
Grade 3–4 adverse events	Myelosuppression (Grade 3)	Leukopenia (Grade 3)	Hypocalcemia, Leukopenia (Grade 3)

Abbreviations: SC squamous cell carcinoma, NACT neoadjuvant chemotherapy, PD-L1 programed death-ligand 1, ICI immune checkpoint inhibitors, Nab-P albumin-bound paclitaxel, P paclitaxel, T carboplatin, Sin sintilimab, pCR pathological complete response, pPR pathological partial response, RH radical hysterectomy, BS bilateral salpingectomy, PLND pelvic lymph node dissection, PALND paraaortic lymph node dissection, CT chemotherapy, CRT chemoradiotherapy

ISSN: 1746-1596